Ureteric stents are used often by Urologists following ureteroscopy for prevention of ureteric obstruction from oedema and or stone fragments. They are often associated with pain, need to void often, the need to urinate quickly and finding blood in the urine called "lower urinary tract symptoms" or LUTS in short. There is randomized studies showing the efficacy of α-blockers such as tamsulosin in relieving "stent symptoms" (pain and LUTS). There is emerging but limited evidence to show that antimuscarinic medications, used to treat overactive bladder (OAB) have some efficacy in decreasing stent symptoms.

Mirabegron is a beta agonist used to decrease OAB symptoms and has been found to be effective in treating patients with stent related symptoms. Mirabegron functions to mediate relaxation of the detrusor muscle. Conventional antimuscarinic medications often have bothersome side effects like dry mouth, constipation, blurred vision and cognitive impairment. This may limit their use in some populations. Mirabegron is well-tolerated with a good safety profile and therefore is useful in treating stent symptoms, without the bothersome side effects commonly seen with antimuscarinic medications. The aim of this study is to compare Tamsulosin and Mirabegron in treating stent related symptoms.